Karsenty Gilles, Reitz André, Lindemann Gertraud, Boy Sönke, Schurch Brigitte
Department of Neuro-Urology, Swiss Paraplegic Center, Balgrist University Hospital, Zurich, Switzerland.
Urology. 2006 Dec;68(6):1193-7. doi: 10.1016/j.urology.2006.08.1069. Epub 2006 Dec 4.
To study the effect of repeated botulinum toxin type A injections into the detrusor in patients with neurogenic detrusor overactivity and incontinence to determine the safety of repeated injections, the persistence of the clinical and urodynamic treatment efficacy, and potential changes in bladder compliance.
Seventeen patients with neurogenic detrusor overactivity who had received three or more botulinum toxin type A injections into the detrusor were studied. The clinical and urodynamic data were analyzed at baseline (before the first injection), after the first injection, and after the last repeated injection.
No systemic side effects were observed for the total of 91 injections. The mean number of injections per patient was 5.4 (range 3 to 9). The mean number of incontinence episodes per day decreased from 2.6 at baseline to 0 after the first injection, and remained at 0 after the last injection. The maximal cystometric bladder capacity and reflex volume increased significantly after the first and last injection compared with at baseline. The maximal detrusor pressure decreased significantly after the first and last injection compared with at baseline. No difference in compliance was found from baseline to the first or last injection.
Repeated injections of botulinum toxin A into the detrusor muscle are a safe and valuable treatment option for neurogenic detrusor overactivity. After repeated injections, the effect on the clinical and urodynamic parameters remained constant. Also, repeated injections did not decrease bladder compliance.
研究对神经源性逼尿肌过度活动和尿失禁患者反复向逼尿肌注射A型肉毒杆菌毒素的效果,以确定反复注射的安全性、临床和尿动力学治疗效果的持续性以及膀胱顺应性的潜在变化。
对17例接受过三次或更多次向逼尿肌注射A型肉毒杆菌毒素的神经源性逼尿肌过度活动患者进行研究。在基线期(首次注射前)、首次注射后以及最后一次反复注射后分析临床和尿动力学数据。
91次注射总计未观察到全身副作用。每位患者的平均注射次数为5.4次(范围为3至9次)。每天尿失禁发作的平均次数从基线期的2.6次降至首次注射后的0次,并在最后一次注射后仍保持为0次。与基线期相比,首次和最后一次注射后最大膀胱测压容量和反射容量显著增加。与基线期相比,首次和最后一次注射后最大逼尿肌压力显著降低。从基线期到首次或最后一次注射,顺应性未发现差异。
反复向逼尿肌注射A型肉毒杆菌毒素是治疗神经源性逼尿肌过度活动的一种安全且有价值的选择。反复注射后,对临床和尿动力学参数的影响保持不变。此外,反复注射并未降低膀胱顺应性。